Pall and ARTeSYN Biosolutions to accelerate the industrialisation of single-use technology

Customers will benefit from the flexibility, agility and reliability required for their bioprocessing journey, says Pall

Filtration, separation and purification company, Pall Corporation, has announced the next step in its collaboration agreement with ARTeSYN Biosolutions, a supplier of single-use components and fluid management technologies.

Under this co-exclusive agreement, Pall Biotech will immediately distribute ARTeSYN’s standard hardware and liner components.

"ARTeSYN valves offer unmatched biopharmaceutical fluid flow control, with a compact, durable single-use design for simple installation and maintenance," notes Michael Gagne, founder and CXO, ARTeSYN Biosolutions.

“This codistribution agreement with ARTeSYN Biosolutions is a critical element of our partnering programme and complements Pall’s existing Allegro integrated single-use portfolio of upstream, downstream and final filling solutions,” said Ed Hoare, Senior Vice President, Pall Biotech.

"The agreement also helps to accelerate the implementation of robust and standardised single-use fluid management and controls, which has been an industry challenge for decades.”

“The adoption of single-use technology continues to grow within the cGMP clinical and commercial manufacturing space. This collaboration reflects our focus on accelerating single-use technology adoption for more efficient production of life saving drugs,” commented Gagne.

“We are excited to work with Pall, a company with which we share similar goals to offer innovative biotech solutions and an outstanding global commercial, technical and validation support network.”

Companies